Looks like you’re on the UK site. Choose another location to see content specific to your location
Biogen’s Zinbryta recommended by NICE for multiple sclerosis
Biogen has announced that its multiple sclerosis (MS) drug Zinbryta has been recommended by the UK's National Institute for Health and Care Excellence (NICE).
The final appraisal determination from the regulator recommends that Zinbryta be considered as a treatment option for patients with active relapsing-remitting MS who have failed to respond to first-line disease-modifying therapy.
It is also endorsed for patients with rapidly evolving severe relapsing-remitting MS, as characterised by the occurrence of two or more relapses a year. Individuals who fit these descriptions will be able to receive Zinbryta through the NHS in England and Wales.
Clinical studies have shown that Biogen's drug can positively impact relapse rates, disability progression, brain lesions and cognitive function in MS, as well as offering a generally manageable safety profile.
The therapy will be made available to eligible patients via the NHS in the coming months.
Terry O'Regan, vice-president and managing director of Biogen in the UK and Ireland, said: "Biogen is delighted that NICE has made the decision to recommend daclizumab as a treatment option for people living with active multiple sclerosis."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard